Pathoquest_logo
  • About Us
    • Why PathoQuest
    • Leadership Team
    • Strategic Partnerships
    • Careers
  • Modalities
    • mAbs and Recombinant Proteins
    • Viral Vectors
    • Cell Therapies
    • Vaccines
    • RNA Therapies
    • Cultivated Meat
  • Services
    • Adventitious Virus Testing
    • In Vivo Replacement
    • Cell Line Characterization
    • Identity Confirmation
    • HLA Genotyping
    • Integration Site Analysis
    • Raw Material Testing
  • iDTECT® Platform
  • 3Rs
  • Quality & Regulatory
    • Quality
    • Regulatory
  • Resources
    • Publications
    • Brochures and Posters
    • Webinars and Talks
    • Our One-Minute Series on NGS
  • News
  • Contact

Webinar Replay – Integration Site Analysis: An innovative method for faster, more certain clone selection & genetic stability testing

by Larry Yost | Oct 23, 2023 | News

CLICK HERE TO LISTEN TO THE WEBINAR REPLAY Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to...

Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency.

by Larry Yost | Sep 14, 2023 | News

Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency PathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...

PathoQuest Announces Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods

by Larry Yost | Sep 6, 2023 | News, Press Release

PathoQuest Announces Publication of a Head-to-Head Study Validating Proprietary NGS Viral Safety Assay as a Reliable Alternative to Animal Testing   NGS assay demonstrated a broader detection range than standard in vivo tests with comparable or higher analytical...

PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. site

by Larry Yost | Aug 21, 2023 | News

PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. site We now offer our GMP validated Viral Vector Identity test at our Wayne, PA site, as well as at our site in Paris, France. Our NGS-based identity test is performed on a short read...

PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blog

by Larry Yost | Aug 17, 2023 | News

PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blog A new post on Charles River’s Eureka science blog feature’s PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf,...

Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation Podcast

by Larry Yost | Aug 4, 2023 | News

Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation Podcast Discover how PathoQuest enables new biotherapies to be delivered rapidly and safely to patients with its quality testing platform in this episode of the AWS Health Innovation...
« Older Entries
Next Entries »

Home » News » Page 3

T: +33 (0)1 70 82 17 90
T: +1 484 212 9360

Copyright © 2024 – PathoQuest | Cookies Policy | Privacy Policy

T: +33 (0)1 70 82 17 90
T: +1 484 212 9360

Copyright © 2023 – PathoQuest | Cookies Policy | Privacy Policy

Cleantalk Pixel
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}

Analytical Methods Validation Head contact form

Name(Required)
Max. file size: 50 MB.
Max. file size: 50 MB.